Search clinical trials for: Cetuximab-IRDye800

Total 3101 results

Bristol-Myers Squibb

Completed

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Head and Neck Cancer | Colorectal Cancer

United States
Lecia V. Sequist
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Terminated

Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy

Non-small Cell Lung Cancer

United States
Maastricht Radiation Oncology
Merck Sharp & Dohme LLC; Academisch Ziekenhuis Maastricht

Completed

Phase I Cetuximab and Concurrent Radio-chemotherapy

Non-small Cell Lung Cancer

Netherlands
Haruhiko Fukuda
Ministry of Health, Labour and Welfare, Japan

Completed

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Lymphoma, B-Cell

Japan
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy of Individualized Rituximab in Maintaining Remission of Moderate and Severe Systemic Lupus Erythematosus

Autoimmune Diseases

China
Korea Cancer Center Hospital
Gachon University Gil Medical Center; The Catholic University of Korea; Gangnam... and other collaborators

Unknown

Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis

Rectal Cancer | Liver Metastasis | Lung Metastasis

Korea, Republic of
Swiss Group for Clinical Cancer Research

Completed

Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery

Esophageal Cancer

Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Peking University

Recruiting

Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

Liver Metastasis Colon Cancer | MSS | ctDNA Genotype | Failed From Standard Treatment

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer

Colorectal Cancer

United States
Eli Lilly and Company
University of Colorado, Denver; Indiana University; Greenwich Hospital

Completed

Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
The University of Texas Health Science Center at...

Completed

Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Carcinoma, Squamous Cell of Head and Neck

United States
Menarini Group

Completed

MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (C-PRECISE-01)

Metastatic Colorectal Cancer

Spain, Italy, Netherlands, Germany, United States, France, Poland
Ruijin Hospital
Henan Cancer Hospital; Second Affiliated Hospital, School of Medicine, Zhejiang... and other collaborators

Unknown

Cetuximab Monotherapy Maintenance Treatment in mCRC

Colorectal Cancer
Eli Lilly and Company

Completed

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, United States, Canada
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer

Gastric Cancer

Germany
Fudan University

Recruiting

Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Colorectal Cancer | Liver Metastases

China
University of Washington
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Refractory Lymphoma | DLBCL | MYD88 Gene Mutation | Relapse | CD79A Gene Mutation | CD79B Gene Mutation
The Lymphoma Academic Research Organisation
Roche Pharma AG

Completed

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (FLIRT)

Follicular Lymphoma

France
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Assistance Publique - Hôpitaux de Paris

Completed

Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis (MAINRITSAN 2)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis | Renal Limited Forms

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Indolent Adult Non-Hodgkin... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Janssen, LP

Completed

Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma

CD20 Positive | Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Ann Arbor Stage II Marginal Zone Lymphoma | Ann Arbor Stage III Marginal... and other conditions

United States
mAbxience Research S.L.
Laboratorio Elea Phoenix S.A.; Libbs Farmacêutica LTDA; Innogene Kalbiotech Pte... and other collaborators

Completed

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Diffuse Large B-cell Lymphoma

Malaysia, Argentina, Colombia, India, South Africa, Philippines, Brazil, Russian Federation, Indonesia, Iran, Islamic Republic of, Mexico, Paraguay
Kuopio University Hospital

Completed

Patients With Rheumatoid Arthritis (RA) Treated With Rituximab in Kuopio University Hospital (KuoRituxi1)

Rheumatoid Arthritis

Finland
Amgen

Completed

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Arthritis, Rheumatoid

United States, Germany, Bulgaria, Hungary, Poland, Estonia
University Health Network, Toronto
AstraZeneca; NeoGenomics Laboratories

Recruiting

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN)

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Canada
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
Nektar Therapeutics

Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Cervical Cancer | Colorectal Cancer | Head and Neck Squamous Cell Carcinoma | Anal Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
The Methodist Hospital Research Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients (ICE)

Breast Cancer

United States
Federation Francophone de Cancerologie Digestive

Completed

Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery

Colorectal Cancer

France
Eli Lilly and Company

Completed

A Study in Advanced Solid Tumors

Solid Tumor

United States, Canada
Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Completed

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

China
Washington University School of Medicine

Completed

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer (SCCHN)

Carcinoma, Squamous Cell

United States
Merck KGaA, Darmstadt, Germany
Choice Pharma Taiwan

Completed

A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)

Carcinoma, Squamous Cell of Head and Neck

Taiwan
West China Hospital

Recruiting

Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer

BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Gastric Cancer | Esophageal Cancer

United States
Ludwig-Maximilians - University of Munich
Sanofi; Merck Sharp & Dohme LLC; Pfizer; Hoffmann-La Roche

Completed

Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Metastatic Colorectal Cancer
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (NEOPECS)

Locally Advanced Cutaneous Squamous Cell Carcinoma
National Cancer Institute (NCI)

Completed

Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma

United States
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Shandong Cancer Hospital and Institute
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; RenJi Hospital and other collaborators

Completed

Erbitux Combined With Chemo-radiotherapy in Esophageal Squamous Cell Carcinoma (EXCEL)

Esophageal Cancer

China
Royal Marsden NHS Foundation Trust
Merck Serono International SA

Terminated

A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU) (PERU)

Pancreatic Cancer

United Kingdom
Sanofi

Recruiting

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Solid Tumor

United States, Israel, Netherlands, Spain
Trisha Wise-Draper
AstraZeneca

Active, not recruiting

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Metastatic Cancer | Recurrent Head and Neck Cancer

United States
Hadassah Medical Organization
Merck Serono International SA

Terminated

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

Cancer of Colon

Israel
National Cancer Institute (NCI)

Completed

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

Colon Cancer | Colonic Neoplasms | Colonic Cancer | Cancer of the Colon | Colon Neoplasms

United States
NanoCarrier Co., Ltd.

Completed

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

United States, Hungary, Romania, Bulgaria

Search clinical trials for: Cetuximab-IRDye800

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations